Genelux Corporation
GNLXHealthcare|Biotechnology|US
$1.96
+0.14 (+7.69%)
Tangible Book / Share
$0.36
Cash / Share
$0.42
Financials
Financial Snapshot
Market Cap
$88.7M
Enterprise Value
$81.9M
Revenue (TTM)
$8.0K
Net Income (TTM)
-$33.8M
Cash & Investments
$18.7M
Net Cash
$16.3M
Free Cash Flow (TTM)
-$28.7M
Operating CF (TTM)
-$25.3M
Debt/Equity
0.15
Cash Runway & Burn Rate
Cash on Hand
$18.7M
Quarterly Burn
$6.3M
Monthly Burn
$2.1M
Est. Runway
~3.0 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $425.0K | $11.3M | $4.5M | $397.0K | $23.2M | $30.9M | $14.6M | $18.7M | |
| Operating Cash Flow | -$7.2M | -$7.2M | -$6.6M | -$3.6M | -$20.3M | -$21.2M | -$25.3M | -$25.3M | |
| Free Cash Flow | -$9.0M | -$7.2M | -$6.6M | -$3.6M | -$21.3M | -$21.6M | -$26.4M | -$28.7M | |
| Capital Expenditure | -$1.8M | -$20.0K | $0.00 | -$49.0K | -$1.0M | -$381.0K | -$1.1M | -$3.4M | |
| Financing Cash Flow | $7.9M | $18.1M | -$270.0K | -$478.0K | $44.0M | $28.5M | $9.9M | $19.2M |
R&D Spending
R&D (TTM)
$22.1M
R&D Intensity
276837.5%
R&D Growth vs Prior
+11.6%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $11.1M | $170.0K | $8.0K | $8.0K | $8.0K | |
| R&D Expense | $7.5M | $6.2M | $6.3M | $9.1M | $12.8M | $19.0M | $19.9M | $22.1M | |
| R&D % of Revenue | — | — | — | 82.0% | 7510.0% | 237475.0% | 248137.5% | 276837.5% | |
| SG&A | $3.3M | $6.2M | $8.3M | $5.0M | $11.6M | $12.7M | $13.4M | $13.5M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $11.1M | $170.0K | $8.0K | $8.0K | $8.0K | |
| Cost of Revenue | $0.00 | $658.0K | $895.0K | $968.0K | $1.0M | $903.0K | $574.0K | $149.0K | |
| Gross Profit | $0.00 | -$658.0K | -$895.0K | $10.1M | -$848.0K | -$895.0K | -$566.0K | -$141.0K | |
| R&D | $7.5M | $6.2M | $6.3M | $9.1M | $12.8M | $19.0M | $19.9M | $22.1M | |
| SG&A | $3.3M | $6.2M | $8.3M | $5.0M | $11.6M | $12.7M | $13.4M | $13.5M | |
| Operating Income | -$10.9M | -$12.4M | -$14.6M | -$3.0M | -$24.2M | -$31.7M | -$33.2M | -$35.6M | |
| Interest Expense | $761.0K | $1.2M | $1.8M | $1.4M | $4.0M | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$11.6M | -$13.6M | -$16.4M | -$4.1M | -$28.3M | -$29.9M | -$32.1M | -$33.8M | |
| Net Income | -$11.6M | -$14.9M | -$17.8M | -$5.2M | -$28.3M | -$29.9M | -$32.1M | -$33.8M | |
| EPS (Diluted) | -0.49 | -0.58 | -0.69 | -0.21 | -1.16 | -0.95 | -0.86 | -0.89 | |
| EBITDA | -$10.4M | -$11.8M | -$13.7M | -$1.7M | -$26.5M | -$29.0M | -$31.6M | -$34.1M | |
| Shares Out. (M) | 23.62 | 23.62 | 23.62 | 24.55 | 24.43 | 31.45 | 37.18 | 44.96 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $425.0K | $11.3M | $4.5M | $397.0K | $9.4M | $8.6M | $5.3M | $9.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $13.8M | $22.3M | $9.3M | $9.5M | |
| Total Current Assets | $551.0K | $11.5M | $5.8M | $1.9M | $24.2M | $31.5M | $15.1M | $19.1M | |
| Total Assets | $3.3M | $14.0M | $8.1M | $5.5M | $27.9M | $34.7M | $19.0M | $26.2M | |
| Total Current Liabilities | $14.7M | $14.5M | $22.5M | $31.6M | $6.6M | $6.9M | $6.2M | $8.0M | |
| Long-Term Debt | $13.0M | $21.7M | $18.0M | $8.5M | $0.00 | $0.00 | $0.00 | $2.1M | |
| Total Liabilities | $28.1M | $36.7M | $41.2M | $41.3M | $8.4M | $8.4M | $7.5M | $10.1M | |
| Stockholders' Equity | -$24.8M | -$22.7M | -$33.1M | -$35.8M | $19.5M | $26.3M | $11.5M | $16.1M | |
| Retained Earnings | -$154.6M | -$168.2M | -$184.6M | -$189.8M | -$221.5M | -$251.4M | -$283.5M | -$301.9M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.2M | -$7.2M | -$6.6M | -$3.6M | -$20.3M | -$21.2M | -$25.3M | -$25.3M | |
| Capital Expenditure | -$1.8M | -$20.0K | $0.00 | -$49.0K | -$1.0M | -$381.0K | -$1.1M | -$3.4M | |
| Free Cash Flow | -$9.0M | -$7.2M | -$6.6M | -$3.6M | -$21.3M | -$21.6M | -$26.4M | -$28.7M | |
| Investing Cash Flow | -$1.8M | -$20.0K | $0.00 | -$49.0K | -$14.7M | -$8.1M | $12.1M | $8.7M | |
| Financing Cash Flow | $7.9M | $18.1M | -$270.0K | -$478.0K | $44.0M | $28.5M | $9.9M | $19.2M | |
| Issuance of Stock | $6.4M | $9.0M | $143.0K | $120.0K | $39.6M | $27.8M | $9.9M | $19.2M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $1.5M | $9.2M | -$558.0K | $970.0K | $215.0K | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $5.3M | $4.3M | $2.4M | $5.2M | $6.1M | $5.9M | $7.1M | |
| Net Change in Cash | -$1.1M | $10.9M | -$6.9M | -$4.1M | $9.0M | -$853.0K | -$3.2M | $2.6M |
Dilution Tracker
Shares outstanding grew 57.4% over 5 years — significant dilution
Shares Outstanding
45M
5-Year Share Growth
+57.4%
Stock Issuance (TTM)
$19.2M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 23.62 | 23.62 | 23.62 | 24.55 | 24.43 | 31.45 | 37.18 | 44.96 | |
| Change vs Prior % | — | 0.0% | 0.0% | 4.0% | -0.5% | 28.7% | 18.2% | 20.9% | |
| Stock Issuance | $6.4M | $9.0M | $143.0K | $120.0K | $39.6M | $27.8M | $9.9M | $19.2M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $5.3M | $4.3M | $2.4M | $5.2M | $6.1M | $5.9M | $7.1M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | 91.3% | -498.8% | -11187.5% | -7075.0% | -1762.5% | |
| Operating Margin % | — | — | — | -27.2% | -14214.7% | -396200.0% | -415175.0% | -445200.0% | |
| Net Margin % | — | — | — | -47.0% | -16645.3% | -373362.5% | -401812.5% | -422412.5% | |
| EBITDA Margin % | — | — | — | -15.6% | -15562.9% | -362075.0% | -394637.5% | -426712.5% | |
| FCF Margin % | — | — | — | -32.7% | -12529.4% | -270112.5% | -329575.0% | -358537.5% | |
| ROE % | 46.9% | 65.6% | 53.7% | 14.6% | -145.3% | -113.7% | -278.5% | -195.4% | |
| ROA % | -354.5% | -106.1% | -219.0% | -94.1% | -101.4% | -86.0% | -168.9% | -129.0% | |
| ROIC % | 159.0% | -364.8% | 187.3% | 32.0% | -109.9% | -112.6% | -251.1% | -192.2% | |
| R&D / Revenue % | — | — | — | 82.0% | 7510.0% | 237475.0% | 248137.5% | 276837.5% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | -98.5% | -95.3% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | -36.0% | 1228.5% | -108.4% | -5.5% | 36.8% | |
| Operating Income | 0.0% | -14.3% | -17.6% | 79.4% | -702.0% | -31.2% | -4.8% | |
| Net Income | 0.0% | -27.8% | -19.7% | 70.7% | -443.4% | -5.6% | -7.6% | |
| EPS (Diluted) | 0.0% | -18.4% | -19.0% | 69.6% | -452.4% | 18.1% | 9.5% | |
| Operating Cash Flow | 0.0% | 0.2% | 8.6% | 45.8% | -467.8% | -4.7% | -19.0% | |
| Free Cash Flow | 0.0% | 19.7% | 8.9% | 45.0% | -488.4% | -1.5% | -22.0% | |
| R&D Expense | 0.0% | -17.3% | 1.5% | 43.7% | 40.6% | 48.8% | 4.5% | |
| SG&A Expense | 0.0% | 85.6% | 33.9% | -39.7% | 131.2% | 9.8% | 5.2% | |
| Total Assets | 0.0% | 326.9% | -42.0% | -31.9% | 404.3% | 24.5% | -45.2% | |
| Book Value / Share | 0.0% | 8.7% | -46.2% | -3.9% | 154.7% | 4.8% | -62.8% | |
| Debt | 0.0% | 45.0% | -2.9% | 4.1% | -90.4% | -25.8% | -9.8% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 4.0% | -0.5% | 28.7% | 18.2% |
Valuation
P/E (TTM)At Loss
P/S11085.11
10Y Low / Med / High13.64 / 9277.96 / 20261.21
P/B5.47
10Y Low / Med / High2.82 / 14.04 / 17.58
EV/EBITDAAt Loss
EV/Revenue10239.61
10Y Low / Med / High15.99 / 8440.84 / 19805.21
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$0.36
Net Current Assets / Share
$0.20
Graham Net-Net
$0.19
Cash / Share
$0.42
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -12.55 | -10.60 | -8.91 | -29.29 | -12.08 | -2.48 | -5.07 | -2.20 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 13.64 | 2013.26 | 9277.96 | 20261.21 | 11085.11 | |
| P/B Ratio | -5.85 | -6.41 | -4.39 | -4.22 | 17.58 | 2.82 | 14.04 | 5.47 | |
| EV/EBITDA | -15.66 | -13.60 | -12.15 | -102.23 | -12.68 | -2.33 | -5.02 | -2.40 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 15.99 | 1972.68 | 8440.84 | 19805.21 | 10239.61 |
Analyst Estimates & Quality
Altman Z-Score
-14.70
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $2.6M | $7.8M | $79.0M |
| Net Income | -$30.1M | -$27.9M | -$11.9M |
| EPS | $-0.81 | $-0.75 | $-0.15 |
| # Analysts (EPS) | 4 | 4 | 4 |